A5068320881- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- SARS-CoV-2 and COVID-19 Research
- Polyomavirus and related diseases
- Cytokine Signaling Pathways and Interactions
- Rheumatoid Arthritis Research and Therapies
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Viral Infections and Immunology Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Lung Cancer Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Medical Imaging and Pathology Studies
- Virology and Viral Diseases
- Stroke Rehabilitation and Recovery
- Pleural and Pulmonary Diseases
- Reproductive System and Pregnancy
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Chronic Lymphocytic Leukemia Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Animal Virus Infections Studies
- Macrophage Migration Inhibitory Factor
Sheba Medical Center
2016-2025
Tel Aviv University
2004-2024
Tbilisi State Medical University
2015-2021
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2012
The National Multiple Sclerosis Society and other expert organizations recommended that all patients with multiple sclerosis (MS) should be vaccinated against COVID-19. However, the effect of disease-modifying therapies (DMTs) on efficacy to mount an appropriate immune response is unknown. We aimed characterize humoral immunity in mRNA-COVID-19 MS vaccinees treated high-efficacy DMTs.We measured SARS-CoV-2 IgG using anti-spike protein-based serology (EUROIMMUN) 125 BNT162b2-COVID-19 vaccine...
Background: Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need be carefully assessed. Objective: Characterize safety and occurrence of immediate relapses following COVID-19 in a large cohort MS patients. Methods: We assessed the BNT162b2 adult Results: Between 20 December 2020 25 January 2021, 555 received first dose vaccine 435 second dose. There were three cases infection encountered after...
Background/Aims Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated patterns impairment MS patients with disease duration up to 30 years. Methods 1,500 were assessed by a computerized battery verbal non-verbal memory, executive function, visual spatial perception, attention, information processing speed motor skills. Cognitive was defined as below one standard deviation (SD)...
Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG up to 6 months PfizerBNT162b2 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective was demonstrated untreated MS (N = 76, 100%), treated with Cladribine 48, Dimethyl fumarate 35, Natalizumab 32, Teriflunomide 39, similarly subjects 89, 97.8%). Response decreased Fingolimod 42,...
Multiple sclerosis (MS) is an immune-mediated disease whose precise etiology unknown. Several studies found alterations in the microbiome of individuals with MS, but mechanism by which it may affect MS poorly understood. Here we analyze 129 and find that they harbor distinct microbial patterns compared controls. To study functional consequences these differences, measure levels 1,251 serum metabolites a subgroup subjects unravel metabolite signature separates affected from controls nearly...
Context: Fatigue is one of the most common and disabling symptoms multiple sclerosis (MS); however, there no medication that has been approved specifically to treat MS-related fatigue. Objective: We aimed evaluate effect vitamin D analogue, Alfacalcidol, on Design, settings, participants: This was a randomized, double-blind, parallel group, placebo-controlled trial in patients with clinically definite MS by McDonald criteria conducted single university-affiliated medical center Israel....
<h3>Background</h3> Intravenous immunoglobulin (IVIg) has been reported to reduce disease activity in patients with relapsing-remitting multiple sclerosis. We assessed the effect of IVIg treatment after first neurological event suggestive demyelinative and evaluated occurrence a second attack dissemination time demonstrated by brain magnetic resonance imaging within year from onset. <h3>Methods</h3> conducted randomized, placebo-controlled, double-blind study 91 eligible enrolled 6 weeks...
Measuring brain volume changes over time is an objective and dependable surrogate marker for the pathological processes that damage in relapsing-remitting multiple sclerosis (RRMS). These measures are particularly valuable monitoring long-term impact of immunomodulatory treatments such as cladribine. To evaluate oral cladribine treatment on loss patients with RRMS. This real-world study processed magnetic resonance imaging (MRI) scans using FreeSurfer's recon-all-clinical pipeline leveraging...
Multiple sclerosis (MS) itself and first-line disease modifying therapies do not increase the risk of contracting COVID-19. However, home isolation is likely to result in a significant decrease participation leisure time physical activities an sedentary behavior. Therefore, using online cross-sectional survey we examined impact COVID-19 epidemic on activity (PA) behavior fitness level Israeli cohort people with multiple (PwMS). The PA questionnaire included 10 questions. Specifically,...
People with multiple sclerosis (PwMS) endure walking limitations. To address this restriction, various physical rehabilitation programs have been implemented no consensus regarding their efficacy. Our objective was to report on the efficacy of an integrated tailored program in people categorized according level neurological disability.Retrospective data were examined and analyzed. Specifically, obtained from all patients who participated Multiple Sclerosis Center's 3 week extracted for depth...
Antiviral adaptive immunity involves memory B cells (MBC) and T (MTC). The dynamics of MBC MTC in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescents warrant further investigation.In this cross-sectional longitudinal study, blood-derived responses were evaluated 68 anti-spike IgG-positive mild disease 2019 (COVID-19) at visit 1, between 1 7 months (median 4.1 months) after onset. SARS-CoV-2 IgG was determined by ELISA, SARS-CoV-2-specific receptor binding domain (RBD)...
Background Multiple sclerosis (MS) is a common nontraumatic, neurological, disabling disease that often presents with upper limb dysfunction. Exercise training has resulted in improvement for patients; however, there can be lack of compliance due to access because location and MS experts. Virtual reality (VR) promising technology offer exercise therapy/rehabilitation at distance. This type remote motivational effective patients improve range motion muscle strength those Objective The aim...
Benign multiple sclerosis (BMS) occurs in about 15% of patients with relapsing-remitting (RRMS) that over time do not develop significant neurological disability. The molecular events associated BMS are clearly understood. This study sought to underlie the biological mechanisms BMS. Blood samples obtained from a cohort 31 and 36 RRMS were applied for gene expression microarray analysis using HG-U133A-2 array (Affymetrix). Data analyzed by Partek pathway reconstruction was performed Ingenuity...
Background Multiple sclerosis (MS) may lead to cognitive decline over-time. Objectives Characterize performance in MS patients with long disease duration treated modifying drugs (DMD) relation disability and determine the prevalence of resilience. Methods Cognitive functional outcomes were assessed 1010 DMD-treated at least 10 years from onset. was categorized as high, moderate or low, neurological classified according Expanded Disability Status Scale (EDSS) mild, severe. Relationship...
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. The majority MS patients have relapsing-remitting course with progressive neurological disability that accumulates over years. Intravenous Immunoglobulin (IVIg) has demonstrated benefit in treatment some MS. Concerns about adverse events IVIg, mainly acute renal failure and thromboembolic been raised medical literature. We examined profile IVIg large cohort 293 treated an initial loading dose (0.4 g/Kg...
Multiple sclerosis (MS) is a central nervous system disease in which activated autoreactive T-cells invade the blood brain barrier and initiate an inflammatory response that leads to myelin destruction axonal loss. The etiology of MS, as well mechanisms associated with its unexpected onset, unpredictable clinical course spanning decades, different rates progression leading disability over time, remains enigma. We have applied gene expression microarrays technology peripheral mononuclear...
Background: The rate of post-relapse residual disability in patients with relapsing–remitting multiple sclerosis (RRMS) treated disease-modifying drugs (DMD) has not been studied. Objective: To assess relapse DMD-treated RRMS patients. Methods: We followed presenting acute who received high-dose steroids. Increases Expanded Disability Status Scale (EDSS) at least 2.0, 1.0–1.5 or 0.5 were defined as severe, moderate mild relapses, respectively. proportions the failure to regain pre-relapse...
Abstract Objective To determine whether pediatric‐onset multiple sclerosis (POMS) and adults‐onset (AOMS) patients are different in initial disease severity recovery to investigate the associations with peripheral blood mononuclear cells (PBMCs) transcriptional profiles. Methods Clinical radiological of first second relapses 6‐month were analyzed 2153 (MS) compared between POMS (onset at 8–18years old) AOMS 19–40 years patients. PBMCs transcriptomes 15 gender‐matched 6 months after relapse...
Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined use in secondary progressive (SPMS). However, no information regarding blood transcriptional changes induced by IFN SPMS patients available. Our aim was to identify a subgroup of presenting gene expression signature similar that RRMS who are clinical responders treatment.SPMS (n = 50, 20 treated 30 untreated) were classified using unsupervised hierarchical clustering...